Paxlovid, an antiviral therapy that is prescribed to COVID-19 patients to prevent severe illness, soon will become much more expensive to obtain.

As the medication transitions to the commercial market, Pfizer has set the updated price for a five-day course at $1,390 — more than double the $529 that the federal government had paid for the treatment.

The new pricing was announced in a letter Pfizer sent to pharmacies on Oct. 18, which was obtained by The Wall Street Journal.

COVID-19 REBOUND AFTER PAXLOVID TREATMENT LIKELY DUE TO INSUFFICIENT EXPOSURE TO THE DRUG

"Pricing for Paxlovid is based on the value it provides to patients, providers and health care systems due to its important role in helping reduce COVID-19-related hospitalizations and deaths," Pfizer said in a statement.

Last week, Pfizer announced in a release on its website that it "amended its supply agreement with the U.S. government for Paxlovid" as the emergency use authorization (EUA)-labeled medications are phased out.

Paxlovid’s transition to the commercial market — and to its updated pricing model — is set to begin in November of this year.

"The commercial transition will begin in November 2023, as the U.S. government begins to discontinue the distribution of EUA-labeled Paxlovid," Pfizer wrote. 

UPDATED COVID VACCINES: FDA ANNOUNCES EMERGENCY APPROVAL AND AUTHORIZATION

The company pointed out that the list price of the medication does not necessarily equate to what patients will pay out of pocket.

"As always, Pfizer’s goal is to ensure broad and equitable access to our medicines," the company wrote in the letter. 

"We are working diligently with payers to achieve the best possible formulary placement for Paxlovid, resulting in low out-of-pocket (OOP) costs for patients."

Pfizer said it also plans to offer a copay program for "eligible privately insured patients," who could potentially get the drug for free.

In its own release, Pfizer also referenced a patient assistance program (PAP) in which patients on Medicare and Medicaid — as well as those who don’t have insurance — will receive Paxlovid free of charge through 2024. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Paxlovid is a combination of two antiviral medications, nirmatrelvir and ritonavir. 

Patients with mild to moderate cases of COVID take two doses of each drug for the course of the five-day treatment.

A statement from the U.S. Department of Health and Human Services (HHS) also announced Paxlovid’s upcoming transition.

"HHS will ensure a smooth and predictable transition to the commercial market over the next few months while prioritizing and reserving our HHS-procured treatment courses for people with Medicare and Medicaid, and for those who are uninsured," the HHS wrote in the release.

The date May 11, 2023, marked the official end of the federal public health emergency related to the COVID-19 pandemic.

However, the government’s declaration noted that emergency use authorizations for COVID-related products would not be affected.

"The timing to conclude the EUA is to be determined; it will not conclude on May 11, 2023, with the other declarations."

Fox News Digital reached out to Pfizer for additional comment.

For more Health articles, visit www.foxnews.com/health.

"The Crown" actress Hadyn Gwynne has died. She was 66.

The British screen and stage star was recently diagnosed with cancer. 

Gwynne's agent, Alex Irwin, told The Associated Press she was "surrounded by her beloved sons, close family and friends" at the time of her death early Friday morning.

Prior to rising to fame, Hadyn taught English in Italy. Her breakout role came in the '90s on the sitcom "Drop the Dead Donkey."

BURT YOUNG, ‘ROCKY’ ACTOR, DEAD AT 83

Gwynne played her most memorable roles later in her career. She starred in "Peak Practice" and played Queen Camilla in the royal satire "The Windsors" and lady-in-waiting Susan Hussey in "The Crown."

She also starred opposite Helen Mirren in the 2013 play "The Audience." Gwynne played Prime Minister Margaret Thatcher.

Mirren honored Gwynne in a statement to the AP, saying Gwynne was "a delight as a person and a consummate dedicated actress."

"She was both funny and serious at the same time, a brilliant balancing act that her whole career exemplified. We will miss her very much," Mirren added.

LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS

Gwynne was nominated for numerous awards prior to her death. She received nominations for an Olivier Award and a Tony for her role in the musical "Billy Elliot."

She received three other Oliver Award nominations for her roles in "The Threepenny Opera," "Women on the Verge of a Nervous Breakdown" and "City of Angels."

According to The Associated Press, Gwynne was set to appear in a musical tribute, "Stephen Sondheim’s Old Friends," but withdrew during rehearsals in September due to "sudden personal circumstances."

The musical producer shared a statement with the outlet, calling Hadyn "a truly wonderful person, as well as a phenomenally talented actress and singer." Cameron Mackintosh noted that Friday's performance is dedicated to Gwynne.

The Associated Press contributed to this report.